List of Excipients in Branded Drug COTEMPLA XR-ODT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neos Therapeutics Brands LLC	COTEMPLA XR-ODT	methylphenidate	70165-100	CELLULOSE, MICROCRYSTALLINE
Neos Therapeutics Brands LLC	COTEMPLA XR-ODT	methylphenidate	70165-100	CITRIC ACID MONOHYDRATE
Neos Therapeutics Brands LLC	COTEMPLA XR-ODT	methylphenidate	70165-100	CROSPOVIDONE
Neos Therapeutics Brands LLC	COTEMPLA XR-ODT	methylphenidate	70165-100	ETHYLCELLULOSE

Cotempla XR-ODT Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Cotempla XR-ODT is a differentiated methylphenidate hydrochloride product that combines extended release with an orally disintegrating tablet, or ODT, designed for pediatric ADHD patients who have difficulty swallowing conventional tablets or capsules. Its commercial value depends less on novel pharmacology than on formulation execution: rapid oral disintegration, controlled methylphenidate release, acceptable taste, dose flexibility, and reliable manufacturing.

The core excipient strategy uses a direct-compression ODT platform with mannitol as a palatable diluent, microcrystalline cellulose as a structural binder, crospovidone as a superdisintegrant, colloidal silicon dioxide as a flow aid, magnesium stearate as a lubricant, sucralose as a sweetener, and strawberry flavor. The formulation must balance two competing requirements: the tablet must disintegrate quickly in the mouth, while the methylphenidate particles must provide extended drug release over the dosing interval.[1]

What is Cotempla XR-ODT and how does its formulation work?

Cotempla XR-ODT is an extended-release methylphenidate hydrochloride tablet approved for ADHD treatment in patients ages 6 to 17. It is administered once daily in the morning and is available in 8.6 mg, 17.3 mg, and 25.9 mg strengths.[1]

The product is swallowed after disintegration. It is not intended to be chewed, crushed, or divided because those actions can disrupt the extended-release performance.[1]

Cotempla XR-ODT product profile

Attribute	Product detail
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release orally disintegrating tablet
FDA indication	ADHD
Approved population	Pediatric patients ages 6 to 17
Initial dose	17.3 mg once each morning
Dose adjustment	Weekly increases of 8.6 mg or 17.3 mg
Maximum dose	51.8 mg once daily
Strengths	8.6 mg, 17.3 mg, 25.9 mg
Administration	Place on the tongue; do not chew, crush, or divide
Original applicant	Neos Therapeutics
Current commercial platform	Azurity Pharmaceuticals
NDA	208090
Regulatory category	Schedule II controlled substance

The formulation addresses a practical adherence problem. Many pediatric patients reject tablets or cannot swallow capsules. Cotempla XR-ODT uses saliva-triggered disintegration while retaining the pharmacokinetic objective of once-daily methylphenidate delivery.

What excipients are used in Cotempla XR-ODT?

The FDA prescribing information identifies the following inactive ingredients: mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and strawberry flavor.[1]

Excipient	Likely formulation role	Commercial significance
Mannitol	Water-soluble diluent, mouthfeel modifier, cooling sensation	Supports palatability and rapid tablet breakup
Microcrystalline cellulose	Compression aid and tablet-bulk former	Provides mechanical strength at low tablet mass
Crospovidone	Superdisintegrant	Promotes rapid breakup after saliva exposure
Colloidal silicon dioxide	Glidant and anti-adherent	Improves powder flow and content uniformity
Magnesium stearate	Lubricant	Supports tablet ejection and manufacturing efficiency
Sucralose	High-intensity sweetener	Masks methylphenidate-associated bitterness
Strawberry flavor	Flavor system	Improves pediatric acceptability and product differentiation

The label does not disclose the quantitative concentration of each excipient. That information is generally treated as proprietary unless provided in regulatory filings, patent examples, or technical publications.

Why mannitol is commercially important

Mannitol is well suited to ODT products because it produces a relatively dry, low-hygroscopic matrix with a favorable mouthfeel. Compared with some alternative polyols, mannitol can provide a cooling sensation and a cleaner oral profile. Those characteristics are useful for a pediatric stimulant, where taste and residual mouthfeel can affect repeat use.

Mannitol also supports a compact dosage form. A smaller tablet improves portability and reduces the risk that a child will refuse administration because of tablet size.

Why crospovidone matters

Crospovidone enables rapid liquid uptake and tablet breakup without forming a viscous gel. That characteristic is useful in an extended-release ODT because the external tablet matrix must disintegrate quickly, while the drug-release control must occur through the methylphenidate-containing particles or internal matrix structure.

A poorly selected disintegrant can create two commercial problems:

1. Slow disintegration can reduce patient acceptance.
2. Excessive disruption of the drug-release structure can produce an undesirable release profile.

The excipient system therefore has to be optimized as a platform rather than by maximizing disintegration speed alone.

Why taste masking is a key barrier

Methylphenidate products can have an unpleasant taste. Cotempla XR-ODT uses sucralose and strawberry flavor to reduce bitterness and improve pediatric acceptability. Taste masking is a material barrier for generic competitors because sensory performance is difficult to establish through dissolution testing alone.

A competing product can match the active ingredient, strength, and release duration but still underperform commercially if children reject its taste. Taste, grittiness, residual particles, mouthfeel, and aftertaste can create meaningful switching friction in pediatric ADHD.

What formulation technology protects Cotempla XR-ODT?

The principal technical protection is the combination of ODT administration and extended methylphenidate release. The commercial product is not merely an immediate-release methylphenidate tablet placed in an orally disintegrating format.

The platform requires control over several variables:

• Particle or granule size
• Drug loading
• Release-controlling coating or matrix behavior
• Tablet tensile strength
• Disintegration time
• Moisture uptake
• Taste masking
• Dose uniformity across low and high strengths
• Stability of the flavor and sweetener system
• Packaging protection from humidity

Formulation patents and platform patents

Neos Therapeutics developed a broader orally disintegrating extended-release stimulant platform used in products including Cotempla XR-ODT and Adzenys XR-ODT. Publicly associated U.S. patent families include U.S. Patent No. 8,865,688 and related continuation or divisional filings directed to extended-release orally disintegrating dosage forms and stimulant formulations.[2]

The practical value of these patents depends on claim scope, expiration dates, terminal disclaimers, patent-term adjustment, Orange Book listing status, and whether a generic applicant can design around the claimed formulation. A patent covering a broad ODT architecture may create more competitive value than a narrow claim directed only to a specific flavor or excipient ratio.

What formulation attributes are hardest to design around?

The strongest formulation barriers are usually the attributes that must be demonstrated together:

• Rapid oral disintegration
• Extended methylphenidate release
• Acceptable pharmacokinetic exposure
• Low tablet friability
• Uniform dosage across multiple strengths
• Taste masking without excessive coating or tablet size

A generic applicant may avoid a particular excipient combination while still facing development risk. Changing mannitol, crospovidone, flavor, or lubricant levels can affect hardness, friability, dissolution, and sensory performance.

What is the FDA and Orange Book status of Cotempla XR-ODT?

Cotempla XR-ODT was approved by the FDA in 2017 under NDA 208090 for ADHD in pediatric patients ages 6 to 17.[1] The product is listed in the FDA Orange Book as a prescription drug with a controlled-substance active ingredient.[3]

The regulatory pathway for a generic competitor would generally be an abbreviated new drug application, or ANDA, supported by pharmaceutical equivalence, bioequivalence, manufacturing data, and compliance with applicable labeling requirements. Because Cotempla XR-ODT is an extended-release ODT, the development program may require more extensive in vitro and clinical pharmacokinetic work than an immediate-release tablet.

Does Cotempla XR-ODT have new chemical entity exclusivity?

No. Methylphenidate is an established active ingredient. Cotempla XR-ODT received product-specific value from its dosage form, release profile, and formulation rather than from new chemical entity exclusivity.

The main commercial barriers are therefore patents, regulatory exclusivity, manufacturing know-how, trade secrets, and pediatric product positioning.

What is the patent expiration outlook?

The relevant Neos platform patents were filed well after the original development of methylphenidate and are generally directed to the extended-release ODT formulation technology rather than the active ingredient itself. Patent expiration analysis must account for each issued patent, continuation practice, patent-term adjustment, and any Orange Book-listed patent tied to NDA 208090.[2,3]

The product’s core active-ingredient patent barrier does not exist. Generic entry risk is concentrated in formulation and dosage-form claims.

Are there Paragraph IV challenges to Cotempla XR-ODT?

Publicly visible patent litigation involving Cotempla XR-ODT has been limited compared with major small-molecule products such as blockbuster oncology, diabetes, and immunology drugs. No widely reported settlement has established a market-wide authorized generic or licensed generic launch date for Cotempla XR-ODT.

A Paragraph IV challenge would likely target one or more of the following:

• Invalidity of the ODT formulation claims
• Non-infringement through a different excipient system
• Absence of infringement based on an alternative release-control mechanism
• Obviousness based on prior ODT and methylphenidate references
• Lack of written description or enablement for broad formulation claims

The commercial impact of a Paragraph IV filing would depend on whether the patent holder initiates litigation within the statutory period. A timely lawsuit can trigger a 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions and court rulings.[4]

When does Cotempla XR-ODT lose exclusivity?

Cotempla XR-ODT did not receive the long exclusivity period associated with a new chemical entity because methylphenidate was previously approved. Market protection instead depends on the interaction of:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents.
3. Pediatric exclusivity.
4. Formulation patents.
5. Generic development timelines.
6. Litigation and settlement outcomes.

The FDA granted pediatric labeling for the product’s approved population, but pediatric exclusivity does not convert an old active ingredient into a new chemical entity. It can extend otherwise qualifying listed patents by six months under applicable FDA rules.[3]

Exclusivity timeline

Milestone	Timing
FDA approval	2017
Product protection source	Formulation, dosage form, patent, and regulatory protections
Active ingredient exclusivity	Not available as a new chemical entity
Pediatric positioning	Ages 6 to 17
Generic pathway	ANDA, subject to patent and exclusivity barriers
Primary entry variable	Surviving formulation patents and FDA approval timing

What generic entry risks exist for Cotempla XR-ODT?

Cotempla XR-ODT faces moderate generic risk over the long term. Methylphenidate is widely available, manufacturing know-how is mature, and the clinical indication is well established. The barriers are commercial rather than pharmacological.

High-risk generic entry scenarios

A generic competitor could enter through an ANDA that:

• Uses a different ODT excipient system.
• Uses a different flavor and sweetener combination.
• Employs a separate extended-release matrix.
• Challenges the validity of the listed formulation patents.
• Develops an alternative release profile that satisfies FDA bioequivalence requirements.

The most credible generic threat is likely to come from a company with existing controlled-substance manufacturing, pediatric dosage-form expertise, and access to high-throughput ODT production.

Manufacturing and intellectual-property barriers

Commercial-scale ODT manufacturing creates practical constraints:

• Low tablet hardness can increase breakage during packaging and distribution.
• High compression force can slow disintegration.
• Lubricant overuse can reduce wettability.
• Humidity can damage tablet structure and flavor performance.
• Controlled-substance handling requires quota management, security, serialization, and supply-chain controls.
• Extended-release performance must remain consistent across strengths.

These variables create a manufacturing barrier even where patent claims are narrow. A generic entrant must produce a tablet that works pharmacokinetically and performs acceptably in the mouth.

What commercial opportunities exist for Cotempla XR-ODT excipients?

The most attractive commercial opportunities are formulation-adjacent rather than simple ingredient substitution.

Excipient supplier opportunities

Excipient manufacturers can target:

• Direct-compression grades of mannitol with improved flow.
• Low-moisture excipients for humidity-sensitive ODTs.
• Co-processed mannitol-cellulose systems.
• Faster-acting crospovidone grades.
• Flavor systems with improved bitterness suppression.
• Taste-masking coatings compatible with extended-release particles.
• Lubricants that minimize hydrophobicity.
• Packaging systems that reduce moisture ingress.

A supplier that can demonstrate better disintegration without compromising dissolution has a stronger value proposition than one offering only a lower-cost version of an existing excipient.

Reformulation opportunities

Potential lifecycle products include:

• New flavors, such as berry, vanilla, or neutral flavor.
• Lower-sugar or sugar-free pediatric positioning.
• A smaller tablet for younger children.
• Additional intermediate strengths.
• A higher-strength tablet that reduces pill burden.
• Improved humidity protection.
• A formulation with reduced aftertaste.
• A product designed for children with sensory or swallowing disorders.

Any reformulation would need to preserve the extended-release profile and controlled-substance compliance while producing a clear clinical or adherence advantage.

Licensing opportunities

Licensing opportunities could arise around:

• Alternative ODT platforms.
• Taste-masking technology.
• Pediatric multiparticulate delivery.
• Controlled-release coatings.
• High-speed ODT compression.
• Moisture-resistant packaging.
• Regional commercialization rights.

For an originator or specialty pharmaceutical company, a licensed formulation platform could support an improved methylphenidate product without rebuilding the entire development program.

How does Cotempla XR-ODT compare with competing methylphenidate products?

Product type	Administration	Release profile	Main advantage	Main limitation
Cotempla XR-ODT	Orally disintegrating tablet	Extended release	No conventional swallowing required; once daily	Formulation and sensory complexity
Conventional extended-release tablet	Swallowed tablet	Extended release	Familiar manufacturing and broad availability	Swallowing burden
Extended-release capsule	Swallowed capsule, sometimes sprinkle-compatible	Extended release	Flexible administration for some patients	Requires capsule handling and food instructions
Immediate-release methylphenidate	Swallowed tablet or liquid	Short acting	Dose flexibility and low cost	Multiple daily dosing
Methylphenidate oral solution	Liquid	Usually immediate release	Useful for patients unable to swallow	Taste, dosing, and adherence burden

Cotempla XR-ODT occupies a narrower but defensible segment. Its strongest differentiation is administration convenience, not superior stimulant pharmacology.

What is the revenue exposure and competitive outlook?

Cotempla XR-ODT revenue is exposed to three factors:

1. The size of the pediatric ADHD market.
2. Reimbursement and pharmacy coverage.
3. Generic substitution once formulation patents and regulatory barriers weaken.

The product can command a premium over generic immediate-release methylphenidate when caregivers, prescribers, and payers value once-daily dosing and swallowability. That premium is vulnerable if insurers require step therapy or if competing ODT, liquid, chewable, or sprinkle formulations offer similar convenience at lower cost.

Azurity’s specialty-pharmaceutical model supports continued commercialization of differentiated dosage forms, but the product remains exposed to the limited size of the pediatric-only label and to the high substitution potential of established methylphenidate products.[5]

Key Takeaways

• Cotempla XR-ODT uses methylphenidate hydrochloride in an extended-release ODT dosage form for pediatric ADHD.
• Its listed excipients are mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and strawberry flavor.
• The formulation’s commercial value comes from combining rapid mouth disintegration, extended release, taste masking, and dose uniformity.
• The principal IP barrier is formulation and dosage-form protection, not active-ingredient protection.
• Generic risk is moderate because methylphenidate manufacturing is established, but ODT sensory and release performance create meaningful development barriers.
• The strongest excipient opportunities involve low-moisture direct compression, improved taste masking, faster disintegration, and co-processed excipient systems.
• Lifecycle opportunities include new flavors, smaller tablets, additional strengths, improved packaging, and broader pediatric adherence positioning.

FAQs

Can Cotempla XR-ODT be reformulated with different sweeteners?

Yes. A reformulation could use another high-intensity sweetener or a combined sweetener system, but it would need to preserve taste performance, tablet stability, dissolution, and regulatory comparability.

Which excipient is most important for rapid Cotempla XR-ODT disintegration?

Crospovidone is the principal listed superdisintegrant, while mannitol also contributes to the tablet’s soluble, palatable structure. Performance depends on the complete excipient system and compression process.

Could a generic Cotempla XR-ODT use a different flavor?

Yes. A generic product does not necessarily need to replicate the strawberry flavor if it meets FDA requirements and does not infringe applicable formulation or trademark rights. A different flavor could still affect pediatric acceptance and commercial uptake.

Is Cotempla XR-ODT interchangeable with immediate-release methylphenidate?

No. The products differ in release profile, dosing frequency, pharmacokinetic exposure, and administration instructions. Substitution requires appropriate clinical and regulatory evaluation.

What packaging is most suitable for an extended-release ODT?

Moisture-resistant unit-dose blister packaging is generally well suited because it protects tablet structure, disintegration performance, flavor, and mechanical integrity during storage and distribution.

References

1. U.S. Food and Drug Administration. (2017). Cotempla XR-ODT prescribing information (NDA 208090).
2. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,865,688: Extended-release orally disintegrating tablets.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2023). ANDA submissions: Refuse-to-receive standards and patent certification procedures.
5. Azurity Pharmaceuticals. (n.d.). Cotempla XR-ODT product information.